PharmaVoice
JUNE 16, 2022
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
PharmExec
JUNE 13, 2022
While the pharmaceutical industry has historically lagged behind other industries in the overall shift to programmatic advertising, the pandemic accelerated this transformation to emerging channels like connected TV (CTV).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JUNE 13, 2022
Canary Wharf’s bid to become a new hub for the life sciences sector in the UK has been given a boost following the decision by Genomics England to relocate to the development. The organisation – which analyses sequenced genomes for the NHS and helps researchers access and use data to help identify the causes of disease – will “anchor” the new cluster, according to Canary Wharf Group (CWG), which is behind the initiative.
NY Times
JUNE 13, 2022
The drug, made by Eli Lilly, is already used for rheumatoid arthritis, and could be followed by two more drugs from other companies.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
PharmaVoice
JUNE 15, 2022
Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.
Pharma Times
JUNE 17, 2022
Verzenios in combination with endocrine treats people with early breast cancer who are at high-risk of recurrence
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
NY Times
JUNE 13, 2022
Outside experts will make their recommendations this week on how the agency should rule on applications from Pfizer and Moderna to vaccinate the nation’s youngest children.
Outsourcing Pharma
JUNE 14, 2022
During BIO International, US leaders shared lessons learned from COVID-19, and how government and industry are collaborating to avoid future supply chain crises.
Pharma Times
JUNE 15, 2022
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
pharmaphorum
JUNE 17, 2022
It has now been over six months since the FDA authorized Paxlovid in December 2021 “for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing who are also at high risk for progression to severe COVID-19.” . At the time of authorisation, the United States federal government had already purchased 10 million doses of the drug.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PharmExec
JUNE 13, 2022
Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).
Drug Channels
JUNE 14, 2022
Last week, the authors of a new JAMA study claimed that “prices for new drugs are skyrocketing.” Their research, along with a simultaneously released New York Times op-ed, received widespread media coverage. Links below. But as I explain, the study’s headline conclusion is highly misleading. The authors obscure the real story with mathematical sleight-of-hand that misrepresents the underlying data and overlooks the true nature of today’s pharmaceutical innovations.
Pharma Times
JUNE 13, 2022
First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer
pharmaphorum
JUNE 14, 2022
Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 people in the US. The JAK1/2 inhibitor has been cleared for adults who are severely affected with the condition at a dose of 2mg once-daily, which can be stepped up to 4mg/day if needed, and according to the FDA will “help fulfil a significant unmet need for patients.” It is estimated tha
PharmExec
JUNE 17, 2022
We may be only at the beginning of outcome-measured, value-based healthcare, but this is a chance for pharma organizations to show their mettle as roles are redefined and definitions of ‘value’ are agreed, says Gérard Klop of Vintura.
Drug Channels
JUNE 17, 2022
Today’s guest post comes from Shawn Seamans, Chief Commercial Officer at CoverMyMeds. Shawn discusses how technology can be combined with human intervention to better help patients access, afford, and adhere to their therapies. He then describes how three patients benefited from support solutions. For more information about how CoverMyMeds’ solutions can support the patient journey for your brand, visit their digital commercialization experience.
Pharma Times
JUNE 14, 2022
Funding will enable the development of Spirea’s pipeline of antibody drug conjugate therapeutics for the treatment of solid tumours
pharmaphorum
JUNE 16, 2022
When creating engagement plans for individual Digital Key Opinion Leaders (DOLs), it’s best to look at a range of data-led metrics about each DOL to fine tune the engagement and maximise benefit for all parties. The simplest, and often easiest metrics to obtain, relate to the activity characteristics of the Digital KOL. In Twitter for example, this may equate to the DOL’s activity levels, follower numbers, and so on.
PharmExec
JUNE 16, 2022
Recent increases in employee burnout and turnover must be addressed.
Drug Channels
JUNE 13, 2022
Informa Connect’s IDN & Bio/Pharma Partnering Summit Hybrid Event August 16-17, 2022 | Philadelphia, PA www.informaconnect.com/IDN. Don’t miss the IDN & Bio/Pharma Partnering Summit coming up this summer in Philadelphia, where you'll be part of the important discussions on how to best optimize strategic partnerships to improve patient access and outcomes.
Pharma Times
JUNE 17, 2022
Therapy represents the first STAMP inhibitor for patients with chronic myeloid leukaemia
pharmaphorum
JUNE 15, 2022
The 2nd NSCLC Drug Development Summit returns for its second year to unite biopharma and academic leaders during an exciting era of personalized medicine. The industry is uniting to address mechanisms of drug resistance, spearhead progress in molecular subtyping and define practice-changing drug sequencing and combinations for the largest solid tumor indication, NSCLC.
PharmExec
JUNE 14, 2022
Industry must continue research and development to combat the pandemic.
NY Times
JUNE 15, 2022
As eagerly anticipated as the shots are for some parents, the committee’s meeting is just one step in a process federal regulators must follow before the vaccines could become available to children as young as 6 months old.
Pharma Times
JUNE 14, 2022
The three-year project will focus on molecular representations and computational tools
pharmaphorum
JUNE 16, 2022
In this episode of the pharmaphorum podcast, editor in chief Jonah Comstock welcomes Dr. Jennifer Jones-McMeans, divisional vice president for global affairs for Abbott’s vascular business to discuss diversity and equity in clinical trials. They discuss the nitty-gritty of clinical trial diversity – why it’s been so hard to achieve, why it’s important, and how to overcome the specific barriers to inclusion for different underrepresented communities.
PharmExec
JUNE 17, 2022
Measure tackles infant formula, cosmetics, and diagnostics—plus drug development and access.
Outsourcing Pharma
JUNE 14, 2022
The company has completed its early-phase development and manufacturing facility in Bend, giving it 11 processing suites focused on first steps into the clinic.
Pharma Times
JUNE 15, 2022
The deal will boost CatSci’s ability to deliver best-in-class medicines to patients worldwide
pharmaphorum
JUNE 13, 2022
Parisa “Risa” Vatanka, PharmD, CTTS, senior director of corporate alliances at the American Pharmacists Association (APhA), tells us about the ideal role of pharmacists in patient care and their effort to gain provider status. . Pharmacists are the most accessible, most frequently visited healthcare providers, but despite their contribution to supporting communities’ health, pharmacists lack provider status recognition to be appropriately compensated for their services. “
EMCrit Project
JUNE 16, 2022
NeuroEMCrit dissects the new ASA sICH Guidelines. EMCrit Project by Scott Weingart, MD FCCM.
PharmaTech
JUNE 17, 2022
FDA has issued an Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines in children as young as six months old.
Pharma Times
JUNE 16, 2022
The companies will focus on the development of biomarkers for chronic diseases
pharmaphorum
JUNE 16, 2022
MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to China’s HIBio. The German biotech is handing over rights to CD38-targeted antibody felzartamab for two forms of glomerulonephritis and MOR210, an anti-C5aR1 antibody for autoimmune disorders and some forms of cancer, which are both currently in early-stage clinical testing.
NY Times
JUNE 16, 2022
The drug, crenezumab, failed to prevent early symptoms or slow cognitive decline, the latest setback in the long quest to find effective therapies for the disease.
Expert insights. Personalized for you.
246 
Let's personalize your content